E-resources
-
Seferović, Petar M.; Polovina, Marija; Bauersachs, Johann; Arad, Michael; Gal, Tuvia Ben; Lund, Lars H.; Felix, Stephan B.; Arbustini, Eloisa; Caforio, Alida L.P.; Farmakis, Dimitrios; Filippatos, Gerasimos S.; Gialafos, Elias; Kanjuh, Vladimir; Krljanac, Gordana; Limongelli, Giuseppe; Linhart, Aleš; Lyon, Alexander R.; Maksimović, Ružica; Miličić, Davor; Milinković, Ivan; Noutsias, Michel; Oto, Ali; Oto, Öztekin; Pavlović, Siniša U.; Piepoli, Massimo F.; Ristić, Arsen D.; Rosano, Giuseppe M.C.; Seggewiss, Hubert; Ašanin, Milika; Seferović, Jelena P.; Ruschitzka, Frank; Čelutkiene, Jelena; Jaarsma, Tiny; Mueller, Christian; Moura, Brenda; Hill, Loreena; Volterrani, Maurizio; Lopatin, Yuri; Metra, Marco; Backs, Johannes; Mullens, Wilfried; Chioncel, Ovidiu; Boer, Rudolf A.; Anker, Stefan; Rapezzi, Claudio; Coats, Andrew J.S.; Tschöpe, Carsten
European journal of heart failure, 20/May , Volume: 21, Issue: 5Journal Article
Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM, HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non‐obstructive HCM. A timely treatment is important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have significant implications for therapeutic decision‐making. In addition, new aetiology‐specific treatment options (e.g. enzyme replacement therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in cardiomyopathies.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.